Five-year follow-up of the local autologous transplantation of CD133+ enriched bone marrow cells in patients with myocardial infarction.
BACKGROUND
The implantation of a CD133+ bone marrow cell population into an ischemic myocardium has emerged as a promising therapeutic modality for myocardial regeneration and restoration of ventricular contractility. While previous studies have documented the short-term safety and efficacy of CD133+ cell transplantation in patients with acute myocardial infarction, there are few reports of long-term follow-up results. Here, we present the results of long-term follow-up of our acute myocardial infarction patients who were treated with intramyocardial injection of CD133+ cells after coronary bypass graft.


METHODS
After five years, 13 patients in the cell transplantation group and 5 patients in the control group underwent safety and efficacy investigations by New York Heart Association classification and two-dimensional echocardiography (2D echo).


RESULTS
During the five-year study period, no major cardiac adverse events were reported among patients who received CD133+ stem cells. Regarding efficiency, we observed no statistically significant treatment effects for the echocardiographic parameters [left ventricular end-diastolic and end-systolic volumes, and resting ejection fraction] measured during the follow-up period. However, detailed analysis of regional wall motion revealed an improvement in the Wall Motion Score Index from baseline to the six month follow-up, which was maintained during the follow-up period.


CONCLUSIONS
Taken together, the long-term results of the present study indicate that transplantation of CD133+ is a safe and feasible procedure; however, we could not show any major benefits in our patients. Thus, this issue needs to be addressed by conducting other studies with more patients.
Tehran Heart Center, Tehran University of Medical Sciences, Iran.
Hossein
H
Ahmadi
Maryam Moshkani
MM
Farahani
Azam
A
Kouhkan
Kasra
K
Moazzami
Roghayeh
R
Fazeli
Hakimeh
H
Sadeghian
Mehrnaz
M
Namiri
Manouchehr
M
Madani-Civi
Hossein
H
Baharvand
Nasser
N
Aghdami
D000071916:AC133 Antigen; D015703:Antigens, CD / Q000378:metabolism*; D001854:Bone Marrow Cells / Q000378:metabolism*; D016026:Bone Marrow Transplantation / Q000379:methods; D001026:Coronary Artery Bypass; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy*; D010455:Peptides / Q000378:metabolism*; D016896:Treatment Outcome; D016277:Ventricular Function, Left
D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides